7월 28일 · 실적분석
실적분석
Nautilus Biotechnologies ($NAUT) Q2 2026 Earnings Analysis — Narrower Loss, First Revenue in Company History, Better-Than-Expected EPS
NAUT Nautilus Biotechnologies 실적 요약Nautilus Biotechnologies ($NAUT) reported Q2 results before the market open on July 28, 2026. Earnings per share came in at a $0.11 loss, beating the consensus estimate (a $0.14 per-share loss) by $0.03, while revenue of $200,000 fell short of the $250,000 estimate. That said, this $200,000 represents the first revenue in company history. Net loss narrowed to $14.5 million from $15.0 million a year earlier, and operating expenses fell 7% to $15.9 million. Cash and equivalents stood at $129.2 million at the end of June. However, the commercialization timeline has been pushed back. Through the previous quarter, pre-orders had been slated for late 2026 with full launch in the first half of 2027; in this announcement, the timeline for the flagship Voyager platform was revised to early-2027 pre-orders and mid-2027 shipments, and the 2027 full-launch target for the broad-scale assay was withdrawn. In the immediate wake of the report, the premarket share price hovered around $1.44, down roughly 13% from the prior close of $1.66.
Earnings Scorecard
▸ Revenue: $200,000 (first revenue in company history, below the $250,000 estimate) ❌ Miss
▸ EPS (earnings per share): -$0.11 (a $0.03 improvement versus the -$0.14 estimate) ✅ Beat
▸ Guidance: No quarterly or annual figures provided. Timeline has been pushed back — Voyager pre-orders early 2027, instrument shipments and consumable kits mid-2027. The 2027 full-launch target for the broad-scale assay has been withdrawn (revised schedule to be announced later); tau proteoform full launch mid-2027, AKT1 early access late 2026 with full launch mid-2027, additional oncology assays mid-to-late 2027
▸ Stock reaction: Report released before the open; immediately afterward, the premarket price hovered around $1.44 (approximately -13% versus the prior close of $1.66)
What Went Well
▸ First revenue: Recognized the first $200,000 in revenue in company history
▸ Narrower loss: Net loss of $14.5 million, down from $15.0 million in the year-ago period
▸ Cost discipline: Operating expenses of $15.9 million, down 7% year over year
The most meaningful change is not the size of the numbers but their character. This is a company that has been developing an analytical instrument that reads proteins one molecule at a time (a single-molecule protein analysis platform), and until now it had been a pure development-stage company with no revenue at all. The $200,000 booked this quarter consists of a research grant from the Michael J. Fox Foundation to study the alpha-synuclein protein, plus service revenue from an early-access program (a scheme that lets select customers use the instrument and services ahead of full launch). The amount is small, but it sends the signal that "someone is willing to pay."
The cost side is also moving in the right direction. Operating expenses fell 7% over the past year, and the loss narrowed along with them. For a biotech / instrument-development company with negligible revenue, survival ultimately comes down to how slowly cash is burned, and cash and equivalents of $129.2 million at the end of June represent a substantial share of the {{MARKET_CAP}}. In other words, a meaningful portion of the company's value still sits as cash in the bank. (The company has {{EMPLOYEES}} employees.)
Real-world validation is also underway: Baylor College of Medicine is already running the instrument as the first early-access customer.
What Fell Short
▸ Revenue miss: $200,000 came in below the $250,000 estimate
▸ Timeline slippage: Pre-order and shipment dates pushed back, and the 2027 full-launch target for the broad-scale assay was withdrawn
▸ Cash burn: The structure of a $14.5 million quarterly net loss continues
The commercialization timeline has actually moved further out. Through the previous quarter, the plan had been pre-orders by late 2026 and a full launch in the first half of 2027; in this announcement, pre-orders were revised to early 2027 and instrument shipments along with consumable kits to mid-2027. On top of that, the 2027 full-launch target for the broad-scale assay is no longer being maintained, and the company said the revised schedule would be disclosed later.
The fact that the per-share loss came in smaller than expected is good news, but at a company with revenue of just $200,000, a $0.03 per-share difference is closer to a reflection of slightly delayed spending than evidence that the business is going well. Conversely, the revenue shortfall versus expectations is also hard to read too much into given how small the absolute scale is. That said, it should be noted that analyst coverage on this small-cap stock is thin, so the consensus itself is not very robust. Indeed, the double-digit drop in the premarket price right after the release looks less like a reaction to the fine differences in individual line items and more like the market pricing in the roadmap reset that came alongside them — the pre-order and shipment delays and the withdrawal of the 2027 full-launch target for the broad-scale assay.
The real burden for investors is time. With pre-orders now expected in early 2027 and shipments in mid-2027, meaningful revenue will only begin to show up from the second half of 2027 at the earliest. Until then, roughly $14 million in losses piles up every quarter. Simple division of the $129.2 million in cash works out to just over two years of runway, so even one more slip in the commercialization timeline could bring financing back into the conversation. With the stock sitting in the $1 range, any capital raise would carry a heavy dilution burden for existing shareholders.
The competitive environment is also no pushover. The protein-analysis market already has established mass-spectrometry instrument makers as well as other next-generation protein-analysis companies, meaning Nautilus cannot stop at simply launching the instrument — it has to prove in working laboratories that it is clearly better than the existing approaches.
What Management Said
Management framed the quarter as a transition point, moving from the development stage into a customer-expansion stage, and said the first recognized revenue is the first piece of evidence of that transition. The company also stated it is concentrating resources on accelerating the roadmap for proteoform applications, including tau protein and oncology assays.
One point worth flagging is that, once again, the company did not provide any quarterly or annual revenue or profit guidance. At a stage where products are not yet being sold, that is a natural choice, but it also means there are no hard numbers for investors to hold onto. Instead of numbers, the company spoke in dates. The two dates — early-2027 pre-orders and mid-2027 shipments — effectively serve as the core guidance in this release, and both have slipped relative to the prior quarter's plan. For the foreseeable future, the yardstick by which the market evaluates this company is likely to be not quarterly profit and loss but whether these dates are kept.
Market Reaction and What to Watch
The quarterly numbers themselves were within the expected range, but with the commercialization timeline slipping, the premarket price responded with a double-digit drop right after the release. Revenue of $200,000 and a net loss of $14.5 million were not shocking figures, and the better-than-expected EPS is of a magnitude that can be explained by the pace of spending, yet the stock was pushed from the prior close of $1.66 down to around $1.44. That is because for development-stage companies like this, the stock price is far more sensitive to the commercialization timeline and the cash position than to quarterly results.
In that light, the real content of this release comes down to two things. First, with the first revenue in company history, the business model has, on paper, moved one step from concept to an actual transaction. Second, the roadmap has been reset, lengthening the period investors have to wait. With $129.2 million in cash comfortably exceeding half of the market cap, the market is viewing this company as something close to "an option sitting on top of a cash cushion, waiting for the instrument to launch."
▸ Whether early-access program customers expand beyond Baylor College of Medicine
▸ Whether quarterly operating expenses and the pace of cash burn continue to moderate as they did this quarter
▸ Whether the revised Voyager platform pre-order timing (early 2027) slips any further, and when the revised broad-scale assay schedule is disclosed
▸ Whether concrete progress is announced on the proteoform application roadmap, including tau and oncology assays
면책조항: 본 콘텐츠는 참고 자료이며 투자 권유가 아닙니다. 모든 투자의 책임은 투자자 본인에게 있습니다.
🎯 오늘의 AI 픽 5종목, 무료로 전부 공개합니다
숨기는 것 없이 — 지난 픽의 성적표(S&P500 대비)까지 그대로 보여드립니다